"Happy new year" might not be the way, exactly, to describe the sort of 2005 that oncologists - not to mention their patients - might expect as a result of changes wrought by the Medicare Modernization Act. (BioWorld Financial Watch)

With AstraZeneca plc's failure of Iressa in non-small-cell lung cancer, the winners were Genentech Inc. and partner OSI Pharmaceuticals Inc. and their drug Tarceva - also an epidermal growth factor inhibitor - which was approved for the indication last month. (BioWorld Today)